Immunoassay Market - By Technology (ELISA, CLIA, RIA), Product (Reagent & Kits, Analyzers/Instruments), Specimen (Blood, Saliva, Urine), Application (Oncology, Cardiology), End-use (Hospitals & Clinics, Diagnostic Labs) – Global Forecast, 2024 – 2032

Immunoassay Market - By Technology (ELISA, CLIA, RIA), Product (Reagent & Kits, Analyzers/Instruments), Specimen (Blood, Saliva, Urine), Application (Oncology, Cardiology), End-use (Hospitals & Clinics, Diagnostic Labs) – Global Forecast, 2024 – 2032

Immunoassay Market Size

Immunoassay Market size was valued at over USD 31.3 billion in 2023 and is estimated to expand at 5.3% CAGR from 2024 to 2032, due to the rise in partnerships and collaborations for focusing on innovative diagnostics and therapeutic solutions. Several companies are actively forming alliances to enhance R&D capabilities to improve the sensitivity, specificity, and efficiency of immunoassays. Moreover, these partnerships are continuously driving advancements by leveraging shared expertise, resources, and distribution networks.
 

The collaborative efforts are also addressing the emerging healthcare needs as well as offering more precise and personalized medical interventions. For instance, in January 2024, Fujirebio Holdings and Agappe Diagnostics announced a CDMO partnership to produce CLIA-based immunoassay reagents for Mispa i60 and i121, further enabling the latter to offer a comprehensive locally manufactured chemiluminescence solution in India.

Immunoassays are gaining prominence as diagnostic tools in the medical field and are increasingly being launched for various applications. These tests are developed to detect diseases, monitor therapeutic drugs, and identify biomarkers with higher sensitivity and specificity. With technology advances, immunoassays are becoming more integral in personalized medicine for offering real-time data for patient management.
 

Companies are also continuously innovating and introducing new assays for expanding the scope of early diagnosis and treatment for transforming healthcare outcomes in the near future. For instance, in July 2023, Siemens Healthineers launched the Atellica CI Analyser for immunoassay testing. This innovative analyser was approved by the U.S. FDA for enhancing diagnostic capabilities with advanced features for improving efficiency and accuracy in laboratory testing.
 

On the other side, the high cost of equipment and reagents along with the complexity of procedures in immunoassays are hindering their broader adoption. These challenges are persisting with ongoing efforts to develop more cost-effective and simplified solutions, however accessibility and scalability will continue to be limited in the future.
 

Immunoassay Market Trends

The rising prevalence of chronic conditions, such as diabetes, cardiovascular diseases, and autoimmune disorders will play an ideal role for the market growth. They are being used to detect biomarkers for enabling early diagnosis and monitoring. With chronic diseases continuing to surge, immunoassays are evolving to provide more precise and rapid testing, aiding in effective disease management.
 

Researchers and healthcare providers are also focusing on developing new immunoassay techniques as they are emerging more essential in tailoring personalized treatments and improving patient outcomes as chronic conditions are expected to rise globally. For instance, in 2023, the Centers for Disease Control and Prevention (CDC) reported that six in ten individuals in the U.S. have at least one chronic disease. To that end, immunoassays have grown vital for diagnosis and management while detecting specific biomarkers for aiding in effective treatment strategies.
 

Immunoassay Market Analysis

Based on product, the market size from the reagents & kits segment is poised to expand at 5.1% CAGR from 2024 to 2032. This growth is fueled by their rising usage as integral components of immunoassay procedures for facilitating the detection of specific biomarkers. Researchers and companies are continuously developing new reagents and kits with improved sensitivity and specificity for enhancing the accuracy of immunoassay results. In addition, advancements in technology will continue to drive innovations in reagent and kit development for more efficient and reliable immunoassay methods.
 

In terms of technology, the enzyme-linked immunosorbent assay (ELISA) segment of the immunoassay market is set to reach over USD 23.8 billion by 2032. ELISA methods are continuously being refined for enhanced sensitivity and specificity for allowing the detection of even low concentrations of target molecules. With ongoing efforts, this technology is evolving further to streamline procedures, reduce assay time, and improve automation. Rising advancements to bolster utility in disease diagnosis, drug development, and biomarker discovery will add to the segment growth.
 

In addition, the chemiluminescence immunoassay assay (CLIA) segment is expected to exhibit 6.3% CAGR through 2032. This is due to the growing importance of CLIA in medical diagnostics for their ability to detect antibodies and antigens. Moreover, the continuous advancements for improving sensitivity and reliability for diagnosing various diseases will contribute to the technology demand.
 

On the basis of specimen, the immunoassay market from the blood segment is predicted to witness 5.1% CAGR through 2032. This expansion is due to researchers largely employing blood samples in immunoassays to detect specific biomarkers indicative of various diseases and health conditions. Advancements in immunoassay technology are continuously improving the precision and sensitivity of blood-based assays for enabling earlier and more accurate diagnoses. Blood-based immunoassays will also continue to evolve with ongoing efforts to refine methodologies, expand biomarker panels, and improve point-of-care testing capabilities.
 

Based on application, the infectious diseases segment is projected to reach over USD 18 billion by 2032. Infectious diseases are detected and monitored through immunoassays via a method that relies on antibodies to identify pathogens. Scientists are developing more sensitive immunoassay techniques for enhancing their ability to diagnose infections swiftly and accurately. Rapid advancements for transforming disease surveillance, treatment, and prevention for ensuring timely interventions and improved public health outcomes will favor the segment growth.
 

Meanwhile, the immunoassay market size from the oncology segment is anticipated to record 6.2% CAGR through 2032 due to increasing role in cancer diagnostics for identifying specific biomarkers with high accuracy. Oncology assays are continuously improving through advancements in technology and research. The ongoing evolution is also promising more effective early-stage diagnoses and personalized treatment plans for patients battling cancer.

In terms of end-use, the market value from the hospitals and clinics segment is expected to exceed USD 15.8 billion by 2032. Hospitals and clinics utilize immunoassay technology to diagnose various diseases by employing rapid tests for timely patient care. Moreover, these settings rely on immunoassays with advancements enhancing their accuracy and versatility. Hospitals are also increasingly automated and streamlined, further allowing for quicker turnaround times and broader diagnostic capabilities.

North America immunoassay market size is expected to record 5% CAGR through 2032 driven by the growing demand for innovative diagnostic solutions. The aging population of the region is fueling the demand for healthcare services and diagnostic tools. As a result, companies are continuously expanding their immunoassay product portfolios and investing in R&D activities.
 

Meanwhile, in the U.S. the industry is growing and will reach over USD 17.5 billion by 2032, benefiting from the increasing awareness about the importance of early disease detection. This awareness is driving the demand for advanced diagnostic technologies and encouraging healthcare providers to adopt immunoassays for accurate and timely diagnosis across the country.
 

Asia Pacific immunoassay assay market is set to record 6.2% CAGR over 2024-2032 due to the rising healthcare expenditure. Growing investments are facilitating the increased adoption of advanced diagnostic technologies across healthcare facilities. Surging healthcare spending by governments and private sectors in countries like China, India, and Japan will also add to the regional industry growth.
 

Immunoassay Market Share

These players are developing innovative diagnostic solutions through partnerships and launch initiatives to meet the evolving healthcare demands. These companies are also continuously investing in R&D to enhance immunoassay technologies for driving future advancements in diagnostic accuracy and efficiency.

Immunoassay Market Companies

Foremost players operating in the immunoassay industry are as mentioned below

• Abbott Laboratories
• Agilent Technologies, Inc.
• Becton Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Hologic Inc.
• Luminex Corporation
• PerkinElmer, Inc.
• QIAGEN
• Sysmex Corporation
• Thermo Fisher Scientific Inc.
   

Immunoassay Industry News

•     In November 2023, Medical & Biological Laboratories Co., Ltd., a JSR Life Sciences Company, revealed plans to globally launch the automated mono-test chemiluminescence immunoassay (CLIA) analyzer, iStar 500.
   
•    In August 2023, Thermo Fisher Scientific introduced high-plex luminex assays for multi-omics for facilitating the simultaneous measurement of gene expression and proteins on one platform.
   

The immunoassay market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

Market, By Product

• Reagents & kits
  • ELISA reagents & kits   
  • ELISPOT reagents & kits   
  • Rapid test reagents & kits      
  • Western blot reagents & kits
  • Chemiluminescence immunoassay reagents & kits
  • Immunofluorescence assay reagents & kits
  • Other reagents & kits 
• Analyzers/Instruments
  • Open ended systems
  • Closed ended systems

Market, By Technology

• Enzyme-linked immunosorbent assay (ELISA)
• Chemiluminescence immunoassay (CLIA)
• Radioimmunoassay (RIA)
• Immunofluorescence assay (IFA)
• Western blotting
• ELISpot
• Other technologies

Market, By Specimen

• Blood
• Urine
• Saliva
• Other specimens

Market, By Application

• Infectious diseases
• Oncology
• Endocrinology
• Cardiology
• Autoimmune diseases
• Therapeutic drug monitoring
• Other applications    

Market, By End-use

• Hospitals and clinics
• Diagnostic centers
• Research and academic laboratories
• Homecare settings
• Other end-users

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa